Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

LON/0RN4 stock hub

LON/0RN4 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0RN4is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

39.9M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0RN4

In the news

Latest news · LON/0RN4

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-102

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0RN4 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

152

Groups with data

Currency

SEK

Showing 152 of 152 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Sweden
Country code	UK
Employees	75
Employees Change	-4%
Employees Change Percent	-5.06
Enterprise value	SEK 44.4M
Exchange	London Stock Exchange
Financial currency	SEK
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Isin	SE0009414576
Last refreshed	2026-05-10
Market cap	SEK 39.9M
Price	SEK 1.29
Price currency	SEK
Rev Per Employee	76,437.36x
Sic	2836
Symbol	lon/0RN4
Website	https://www.oncopeptides.com/sv

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-50.49%
EV Earnings	-2.21x
EV/Sales	7.85x
P/B ratio	-8.39x
P/S ratio	6.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	96.55%
Gross Profit	SEK 5.5M
Gross Profit Growth	136.91%
Gross Profit Growth Q	81.93%
Gross Profit Growth3 Y	101.85%
Net Income	SEK -20.1M
Pretax Margin	-348.96%
Profit Per Employee	SEK -268,253
ROA	-74.3
Roa5y	-77.02
ROCE	-249.8
ROIC	-102

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-22.06%
Cagr3y	-36.76%
Cagr5y	-55.99%
Revenue Growth	124.72x
Revenue Growth Q	87.28x
Revenue Growth3 Y	104.18x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	SEK 0.37
Assets	SEK 10.9M
Cash	SEK 6.6M
Current Assets	SEK 9.3M
Current Liabilities	SEK 3.5M
Debt	SEK 11.2M
Equity	SEK -4.7M
Interest Coverage	-15.61
Liabilities	SEK 15.7M
Long Term Assets	SEK 1.6M
Long Term Liabilities	SEK 12.1M
Net Cash	SEK -4.6M
Net Cash By Market Cap	SEK -11.56
Tangible Book Value	SEK -4.7M
Tangible Book Value Per Share	SEK -0.02
WACC	-1.02

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.61
Inventory Turnover	0.39
Net Working Capital	SEK -151,304
Quick ratio	2.19
Working Capital	SEK 5.9M
Working Capital Turnover	SEK 0.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-36.32%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-22.05%
200-day SMA	3.87
3Y total return	-74.71%
50-day SMA	1.47
50-day SMA vs 200-day SMA	50under200
5Y total return	-98.35%
All Time High	211.6
All Time High Change	-99.39%
All Time High Date	2021-03-01
All Time Low	1.27
All Time Low Change	2.05%
All Time Low Date	2026-05-08
ATR	0.04
Beta	-1.43
Ch YTD	-73.02
High	1.33
High52	6.51
High52 Date	2025-10-07
High52ch	-80.12%
Low	1.29
Low52	1.27
Low52 Date	2026-05-08
Low52ch	1.57%
Ma50ch	-11.92%
Price vs 200-day SMA	-66.61%
RSI	36.57
RSI Monthly	36.92
RSI Weekly	28.37
Sharpe ratio	0.29x
Sortino ratio	0.53
Total Return	-36.32%
Tr YTD	-71.41
Tr1m	-4.51%
Tr1w	0.94%
Tr3m	-50.53%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	SEK -18.2M
Operating margin	-317.3

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	379,329,667%
Shares Insiders	0.46%
Shares Institutions	10.04%
Shares Qo Q	15.59%
Shares Yo Y	36.32%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	141,671.25x
Bv Per Share	-0.02
Ch1m	-4.51
Ch1w	0.94
Ch1y	-30.67
Ch3m	-53.32
Ch3y	-83.97
Ch5y	-98.95
Ch6m	-73.37
Change	0.47%
Change From Open	-1.15
Close	1.29
Days Gap	1.63
Depreciation Amortization	196,597.1
Dollar Volume	58,400.9
Earnings Date	2026-04-28
EBIT	SEK -18.2M
EBITDA	SEK -18M
EPS	SEK -0.09
F Score	3
Financing CF	10,362,703
Fiscal Year End	December
Founded	2,000
Income Tax	SEK 114,063
Is Primary Listing	0
Last Earnings Date	2026-04-28
Last Report Date	2025-12-31
Ma150	3.5
Ma150ch	-63.06%
Ma20	1.36
Ma20ch	-4.58%
Net CF	-7,761,185
Next Earnings Date	2026-05-13
Open	1.31
Position In Range	4.76
Ppne	1,407,380.3
Price Date	2026-05-07
Relative Volume	0.32x
Revenue	5,732,802x
SBC By Revenue	3.82x
Share Based Comp	218,936
Tax By Revenue	1.99x
Tr6m	-71.77%
Volume	45,167
Z Score	-62.85

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0RN4 pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0RN4 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0RN4?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.0%

Share of float held by funds and institutions

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+36.3%

Negative means the company is buying back shares.

Technical

LON/0RN4 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

36.6

Neutral momentum band

Price vs 200-day MA

-66.6%

50/200-day relationship not available

Beta (5Y)

-1.43

Less volatile than the market

Sharpe ratio

0.29

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0RN4

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0RN4 stock rating?

lon/0RN4 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0RN4 analysis?

The full report lives at /stocks/lon/0RN4/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0RN4?

The latest report frames lon/0RN4 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0RN4 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.